Completed

See Detailed Description

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Data Collection

Who is being recruted

Acquired Immunodeficiency Syndrome+37

+ Acquired Immunodeficiency Syndrome

+ Acquired Immunodeficiency Syndrome

Over 18 Years
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 3
Interventional
Study Start: May 2004
See protocol details

Summary

Principal SponsorGlaxoSmithKline
Last updated: January 14, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: May 1, 2004

Actual date on which the first participant was enrolled.

A Phase IIIB, Randomized, Open-Label, Multicenter Study of the Safety and Efficacy of GW433908 (700mg BID) plus ritonavir (100mg BID) Versus Lopinavir/ritonavir (400mg/100mg BID) when Administered in Combination with the Abacavir/Lamivudine (600mg/300mg) Fixed-Dose Combination Tablet QD in Antiretroviral-Naive HIV-1 Infected Adults Over 48 Weeks

Official TitleSee Detailed Description 
NCT00085943
Principal SponsorGlaxoSmithKline
Last updated: January 14, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

866 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Acquired Immunodeficiency SyndromeAcquired Immunodeficiency SyndromeAcquired Immunodeficiency SyndromeAcquired Immunodeficiency SyndromeAcquired Immunodeficiency SyndromeAcquired Immunodeficiency SyndromeAcquired Immunodeficiency SyndromeAcquired Immunodeficiency SyndromeCommunicable DiseasesCommunicable DiseasesImmunologic Deficiency SyndromesImmune System DiseasesInfectionsPathologic ProcessesRetroviridae InfectionsRNA Virus InfectionsSexually Transmitted DiseasesSexually Transmitted DiseasesSexually Transmitted DiseasesSexually Transmitted DiseasesSlow Virus DiseasesVirus DiseasesSexually Transmitted Diseases, ViralSexually Transmitted Diseases, ViralSexually Transmitted Diseases, ViralSexually Transmitted Diseases, ViralSexually Transmitted Diseases, ViralHIV InfectionsHIV InfectionsHIV InfectionsHIV InfectionsHIV InfectionsHIV InfectionsHIV InfectionsLentivirus InfectionsDisease AttributesBlood-Borne InfectionsBlood-Borne InfectionsUrogenital DiseasesGenital Diseases

Criteria

Inclusion Criteria: * HIV infected subjects that are naive to anti-HIV therapy. * History of a positive HIV test. * At least 1000 copies/mL of HIV in their blood as screening. Exclusion Criteria: * Active HIV-related diseases. * Taking other investigational drugs. * Pregnant or breastfeeding females. * Not be suitable to participate per investigator opinion.

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Study Objectives

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 120 locations

Suspended

GSK Investigational Site

Birmingham, United StatesSee the location
Suspended

GSK Investigational Site

Phoenix, United States
Suspended

GSK Investigational Site

Los Angeles, United States
Suspended

GSK Investigational Site

Sacramento, United States
Completed120 Study Centers